Market Place
Sourcing Support
Johnson & Johnson Completes Acquisition of Ambrx
07 Mar 2024 //
BUSINESSWIRE
J&J sees ‘opportunities’ in neuro and immunology post-Ambrx buy
23 Jan 2024 //
FIERCE BIOTECH
J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion
09 Jan 2024 //
CNBC
Ambrx Announces Sale to Johnson & Johnson
08 Jan 2024 //
GLOBENEWSWIRE
Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50
23 Oct 2023 //
GLOBENEWSWIRE
Ambrx`s `reset` arrives at the last line of prostate cancer
22 Oct 2023 //
FIERCE BIOTECH
Ambrx Biopharma files $300M mixed securities shelf
18 Oct 2023 //
SEEKING ALPHA
Ambrx Provides Safety and Efficacy Data from Phase 1/2 APEX-01 Trial of ARX517
16 Oct 2023 //
GLOBENEWSWIRE
ESMO 2023 Abstracts Available Here
15 Oct 2023 //
PRESS RELEASE
Ambrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023
26 Sep 2023 //
GLOBENEWSWIRE
Ambrx to Participate in the Cantor Fitzgerald Global Healthcare Conference
18 Sep 2023 //
GLOBENEWSWIRE
Ambrx to Present Preliminary ARX517 First-in-Human Safety Data at ESMO 2023
28 Jul 2023 //
GLOBENEWSWIRE
FDA Grants Fast Track Designation for Ambrx™s ARX517
19 Jul 2023 //
GLOBENEWSWIRE
Ambrx Soars on Synthetic ADC Linker Science
10 Jul 2023 //
SDBJ
Ambrx Appoints Jared Kelly as General Counsel
05 Jun 2023 //
GLOBENEWSWIRE
Ambrx Announces $75 Million Market Priced Registered Offering
24 May 2023 //
GLOBENEWSWIRE
Ambrx Appoints Stephen Glover as Chairman of its Board of Directors
18 May 2023 //
GLOBENEWSWIRE
Ambrx to Present at JMP Securities Life Sciences Conferences
11 May 2023 //
GLOBENEWSWIRE
Ambrx to Present Preclinical Data on ARX517 and ARX305 at the 2023 AACR Meeting
27 Mar 2023 //
GLOBENEWSWIRE
Ambrx Raises $78 Million and Completes its ATM Program
13 Mar 2023 //
BUSINESSWIRE
Ambrx to Commence Trading on Nasdaq
06 Mar 2023 //
BUSINESSWIRE
ACE-Breast-02 Pivotal Phase 3 Study of Ambrx’s ARX788 Achieves Positive Results
01 Mar 2023 //
BUSINESSWIRE
New Ambrx CEO spies a path for ousted breast cancer med
01 Mar 2023 //
FIERCE BIOTECH
ARX517 Shows Encouraging Data in Patients with Advanced Prostate Cancer
16 Feb 2023 //
BUSINESSWIRE
Ambrx to host Investor Day to Discuss ARX788 and ARX517 in Cancer
13 Feb 2023 //
BUSINESSWIRE
Ambrx Appoints Sandra Aung as Head of Clinical Development
03 Feb 2023 //
BUSINESSWIRE
Ambrx Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Price
16 Dec 2022 //
BUSINESSWIRE
Ambrx Shares Surge After Encouraging Early Safety, Efficacy Data From ARX788
10 Dec 2022 //
BUSINESSWIRE
Ambrx Announces Encouraging Preliminary Safety & Efficacy Data Evaluating ARX788
09 Dec 2022 //
BUSINESSWIRE
Ambrx Announces NovoCodex’s Dosing of First Patient with ARX305
09 Nov 2022 //
BUSINESSWIRE
Ambrx Biopharma Appoints Daniel O’Connor as CEO
01 Nov 2022 //
BIOSPACE
Biotech layoffs continue as Ambrx cuts staff & part of pipeline to extend cash
19 Oct 2022 //
ENDPTS
Ambrx dumps lead HER2 asset and lays off 15% of workforce
19 Oct 2022 //
FIERCEBIOTECH
Ambrx Announces Strategic Reprioritization and Provides Corporate Update
18 Oct 2022 //
GLOBENEWSWIRE
Ambrx Biopharma to Host Corporate Update Conference Call
11 Oct 2022 //
GLOBENEWSWIRE
Ambrx Biopharma Reports 1H 2022 Financial Results and Provides Corporate Update
29 Aug 2022 //
BUSINESSWIRE
Uncertainty at Ambrx as biotech loses CEO, reassesses pipeline
17 Aug 2022 //
FIERCEBIOTECH
Ambrx Biopharma Appoints Kate Hermans as Interim CEO, Replacing Feng Tian
16 Aug 2022 //
BUSINESSWIRE
Ambrx Biopharma Appoints Edward Hu and Kate Hermans to its Board of Directors
05 Jul 2022 //
BUSINESSWIRE
Ambrx Biopharma to Present at H.C. Wainwright PCDD Conference
28 Jun 2022 //
BUSINESSWIRE
Ambrx Biopharma Inc. Appoints Janet Loesberg to Board of Directors
06 Jun 2022 //
BUSINESSWIRE
Ambrx Biopharma Inc. to Participate in Upcoming Investor Conferences
27 May 2022 //
BUSINESSWIRE
Ambrx Biopharma Inc. Appoints Janice Lu, M.D., Ph.D., as Chief Medical Officer
17 May 2022 //
BUSINESSWIRE
Ambrx Biopharma Inc. to Present at Upcoming Investor Conferences
06 May 2022 //
BUSINESSWIRE
Ambrx Biopharma Inc. Announces Filing of Annual Report on Form 20-F
02 May 2022 //
BUSINESSWIRE
Ambrx Biopharma Reports FY 2021 Financial Results; Provides Corporate Update
26 Apr 2022 //
BUSINESSWIRE
Ambrx Biopharma Inc. and Quantum Leap Healthcare Collaborative™
25 Apr 2022 //
PRNEWSWIRE
Ambrx Biopharma to Release Full Year 2021 Financial Results on Tuesday
21 Apr 2022 //
BUSINESSWIRE
Ambrx Biopharma to Present at Oppenheimer’s 32nd Annual Healthcare Conference
08 Mar 2022 //
BUSINESSWIRE
Ambrx Biopharma to Participate in the Cowen 42nd Annual Health Care Conference
28 Feb 2022 //
BUSINESSWIRE
Ambrx Biopharma Submits IND Application for ARX305 with the U.S. FDA
15 Feb 2022 //
BUSINESSWIRE
Ambrx Appoints Paul Maier to Board of Directors as Chair of Audit Committee
07 Feb 2022 //
BUSINESSWIRE
Ambrx Presents Positive Data from Ongoing Phase 1 Clinical Study of ARX788
09 Dec 2021 //
BUSINESSWIRE
Ambrx Biopharma Inc. Announces Acceptance of Two Poster Presentations at 2021
19 Nov 2021 //
BUSINESSWIRE
Bristol Myers becomes latest victim of unforgiving NASH
18 Nov 2021 //
FIERCEBIOTECH
Ambrx Biopharma begins dosing in Phase II trial of breast cancer treatment
04 Nov 2021 //
CLINICALTRIALSARENA
Ambrx Biopharma Inc. Reports 1H 2021 Financial Results
28 Oct 2021 //
BUSINESSWIRE
Ambrx Announces Positive Data on ARX788 for HER2+ Gastric Cancer at CSCO
04 Oct 2021 //
BUSINESSWIRE
Ambrx Announces Positive Data on ARX788 for HER2+ Gastric Cancer at CSCO
04 Oct 2021 //
BUSINESSWIRE
Ambrx to Participate at the H.C. Wainwright 23rd Annual Investment Conference
09 Sep 2021 //
BUSINESSWIRE
